Abstract
BackgroundAripiprazole, a third-generation antipsychotic medication, has been used to treat a range of psychiatric disorders. According to the U.S. Food and Drug Administration’s prescribing information, the most common adverse reactions in adult patients in clinical trials (≥10%) were nausea, vomiting, constipation, headache, dizziness, akathisia, anxiety, and insomnia. While hematological adverse effects may occur with aripiprazole, there is very limited information in the published literature on such adverse outcomes.Case presentationA 68-year-old Caucasian male with treatment resistant depression was hospitalized for suicidal ideation. The patient developed neutropenia after aripiprazole was introduced as an augmentation agent. The neutropenia was reversible with discontinuation of the medication.ConclusionsTo our knowledge, we describe the first case report of suspected neutropenia-induced by aripiprazole use in a geriatric patient. While hematological adverse reactions are rare, we recommend adding CBC to the standard adverse systemic reaction monitoring of antipsychotic medications, particularly among the elderly.
Highlights
Aripiprazole, a third-generation antipsychotic medication, has been used to treat a range of psychiatric disorders
To our knowledge, we describe the first case report of suspected neutropenia-induced by aripiprazole use in a geriatric patient
Aripiprazole has been approved by the U.S Food and Drug Administration (FDA) for treatment of schizophrenia, bipolar mania, Tourette’s disorder, irritability associated with autism spectrum disorder, and adjunct to antidepressants in treatment of major depressive disorder [1,2,3]
Summary
We describe the first case report of suspected neutropenia-induced by aripiprazole use in a geriatric patient.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call